What are the specific aspects of the efficacy of lapatinib/telisa

Lapatinib (Lapatinib) is an oral small molecule targeted drug originally developed by GlaxoSmithKline (GSK) for the treatment of patients with HER2-positive breast cancer. Its main effect is to block cancer cell proliferation signals by inhibiting two key signal receptors on the tumor cell membrane—human epidermal growth factor receptor (EGFR) and HER2 (ErbB2)—so as to delay tumor growth and inhibit metastasis. As a dual-target inhibitor, lapatinib has more comprehensive anti-tumor activity than early single-target drugs, which makes it occupy an important position in the comprehensive treatment of HER2-positive breast cancer.

The efficacy of lapatinib is mainly reflected in its ability to effectively interfere with the internal signaling of cancer cells. HER2-positive breast cancer cells often exhibit abnormal overexpression of HER2 protein, which drives unrestricted cell division. Lapatinib reversibly binds to the ATP binding sites of HER2 and EGFR, inhibiting the activation of downstream signaling pathways such as MAPK and PI3K/AKT pathways, fundamentally interrupting the growth-driving mechanism of cancer cells. In addition, unlike antibody drugs such as Trastuzumab, lapatinib is a small molecule drug that can penetrate cell membranes, so it can still play a therapeutic role in some patients with drug resistance or brain metastases. This is one of its outstanding clinical advantages.

In research, lapatinib is often used in combination with chemotherapy drugs such as capecitabine (Capecitabine) to improve the tumor suppression effect. When some patients develop drug resistance after trastuzumab treatment, switching to the lapatinib regimen can still achieve the effect of delaying disease progression, demonstrating its potential value in drug resistance management. In addition, lapatinib has also been explored for use in other cancers with high HER2 expression, such as gastric cancer and cholangiocarcinoma. Although it is still in the research stage, preliminary results show good anti-tumor activity.

Reference materials:https://medlineplus.gov/druginfo/meds/a607055.html